{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:00:54Z","timestamp":1761505254776,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.3816\/clc.2009.n.011","type":"journal-article","created":{"date-parts":[[2009,4,11]],"date-time":"2009-04-11T21:01:57Z","timestamp":1239483717000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Second-Line Therapy for Non\u2013Small-Cell Lung Cancer"],"prefix":"10.3816","volume":"10","author":[{"given":"Belisario A.","family":"Arango","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio B.","family":"Castrellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2009.n.011_bib1","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CLC.2009.n.011_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLC.2009.n.011_bib3","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib4","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.3816\/CLC.2009.n.011_bib6","first-page":"622s","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancers (NSCLC) following failure on 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCICCTG) trial","volume":"22","author":"Shepherd","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib7","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.1995.13.3.645","article-title":"Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer","volume":"13","author":"Fossella","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib9","first-page":"335a","article-title":"Phase II trials of Taxotere with non-small cell lung cancer","volume":"12","author":"Burris","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib10","first-page":"454a","article-title":"Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial","volume":"16","author":"Gandara","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib11","first-page":"480a","article-title":"Phase II study of docetaxel (Taxotere) in firstand second-line NSCLC","volume":"16","author":"Robinet","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib12","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib13","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib14","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1200\/JCO.2005.02.3739","article-title":"Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel","volume":"23","author":"Schuette","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib15","first-page":"388s","article-title":"Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: updated report with survival","volume":"25","author":"Fidias","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1385\/MO:21:3:233","article-title":"Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial","volume":"21","author":"Tas","year":"2004","journal-title":"Med Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib17","first-page":"1116","article-title":"LY231514, a pyrrolo [2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib18","first-page":"2598","article-title":"Activity of LY231514 against several enzymes in the folate-dependent pathways","volume":"37","author":"Chen","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/14796694.1.6.733","article-title":"Clinical activity of Pemetrexed: a multitargeted antifolate anticancer agent","volume":"1","author":"Solomon","year":"2005","journal-title":"Future Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib20","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.3816\/CLC.2009.n.011_bib21","first-page":"86","article-title":"Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)","volume":"9","author":"Clarke","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLC.2009.n.011_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1359-6349(07)71349-6","article-title":"Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC)","volume":"5","author":"Peterson","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLC.2009.n.011_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/annonc\/mdm592","article-title":"A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"19","author":"Cullen","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib25","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-06-2393","article-title":"Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer","volume":"13","author":"Takimoto","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"10.3816\/CLC.2009.n.011_bib26","first-page":"426s","article-title":"Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study","volume":"26","author":"Ciuleanu","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib27","first-page":"685s","article-title":"A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer","volume":"25","author":"Waples","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib28","first-page":"508","article-title":"Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies","volume":"11","author":"Molina","year":"2008","journal-title":"IDrugs"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib29","first-page":"608s","article-title":"Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non small cell lung cancer","volume":"25","author":"Azzoli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib31","first-page":"203","volume":"61","author":"Ulrich","year":"1990","journal-title":"Signal transduction by receptors with tyrosine kinase activity"},{"key":"10.3816\/CLC.2009.n.011_bib32","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J Biol Chem"},{"key":"10.3816\/CLC.2009.n.011_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/jnci\/90.11.799","article-title":"Prognostic applications of the epidermal growth factor receptor and its ligands, transforming growth factor-alfa","volume":"90","author":"Wikstrand","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLC.2009.n.011_bib34","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib35","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.3816\/CLC.2009.n.011_bib36","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLC.2009.n.011_bib37","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/01243894-200611000-00008","article-title":"The role of gefitinib treatment for Korean neversmokers with advanced or metastatic adenocarcinoma of the lung: a prospective study","volume":"1","author":"Lee","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib39","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib40","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib41","first-page":"196","article-title":"Rash severity is predictive of increased survival with erlotinib HCL","volume":"22","author":"Clark","year":"2003","journal-title":"Proc Am Soc Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib42","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib patients with non-small cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated nonsmall-cell lung cancer","volume":"2","author":"Shepherd","year":"2005","journal-title":"New Eng J Med"},{"key":"10.3816\/CLC.2009.n.011_bib44","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib45","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0959-8049(02)00013-8","article-title":"Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in nude mouse model","volume":"38","author":"Jung","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLC.2009.n.011_bib46","first-page":"3739","article-title":"Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib47","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase I\/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER1\/Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib48","doi-asserted-by":"crossref","unstructured":"Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory nonsmall cell lung cancer. J Clin Oncol 200; 24(18 suppl):379s (Abstract 7062).","DOI":"10.1200\/jco.2006.24.18_suppl.7062"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib49","first-page":"432s","article-title":"Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase I-IIa dose-ranging study from the Hossier Oncology Group","volume":"25","author":"Jalal","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib50","first-page":"420s","article-title":"Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"25","author":"Belani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLC.2009.n.011_bib51","first-page":"6s","article-title":"FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin\/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)","volume":"26","author":"Pirker","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib52","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-006-0257-y","article-title":"Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma","volume":"59","author":"Carter","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib54","first-page":"676s","article-title":"A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC)","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib55","first-page":"364s","article-title":"Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma","volume":"24","author":"Gatzemeier","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CLC.2009.n.011_bib56","first-page":"220s","article-title":"Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors","volume":"23","author":"Steinbild","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CLC.2009.n.011_bib57","first-page":"712s","article-title":"Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients","volume":"23","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib58","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-06-2889","article-title":"Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer","volume":"13","author":"Adjei","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib59","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib60","first-page":"364s","article-title":"Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial","volume":"24","author":"Socinski","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-06-0416","article-title":"Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade","volume":"6","author":"Wu","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib62","first-page":"363s","article-title":"ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial","volume":"24","author":"Natale","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib63","first-page":"368s","article-title":"A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results","volume":"24","author":"Heymach","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLC.2009.n.011_bib64","first-page":"422s","article-title":"Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer: An open label multicenter phase I study","volume":"25","author":"De Boer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1158\/1535-7163.MCT-07-2068","article-title":"Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells","volume":"7","author":"Kim","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CLC.2009.n.011_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.critrevonc.2005.12.001","article-title":"Proteasome inhibitors in lung cancer","volume":"58","author":"Scagliotti","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.3816\/CLC.2009.n.011_bib68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ejca.2007.01.038","article-title":"The proteasome: A worthwhile target for the treatment of solid tumours?","volume":"43","author":"Milano","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLC.2009.n.011_bib69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1556-0864(15)31527-6","article-title":"Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial","volume":"1","author":"Lara","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib70","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2009.n.011_bib71","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.3816\/CLC.2009.n.011_bib72","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ijc.21932","article-title":"Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells","volume":"119","author":"Beevers","year":"2006","journal-title":"Int J Cancer"},{"key":"10.3816\/CLC.2009.n.011_bib73","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-06-2570","article-title":"Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors","volume":"13","author":"Granville","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2009.n.011_bib74","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor Erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CLC.2009.n.011_bib75","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411700869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411700869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:56:40Z","timestamp":1761505000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411700869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1525730411700869"],"URL":"https:\/\/doi.org\/10.3816\/clc.2009.n.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Line Therapy for Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2009.n.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}